AbCellera Biologics Inc. Common Shares

ABCLNASDAQUSD
7.38 USD
0.72 (10.81%)AT CLOSE (11:59 AM EDT)
7.40
0.02 (0.29%)
POST MARKET (AS OF 08:00 PM EDT)
Post Market
AS OF 08:00 PM EDT
7.40
0.02 (0.29%)
🔴Market: CLOSED

AbCellera Biologics Inc. Common Shares (ABCL) trades at $7.38 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics place ABCL at a fair price relative to peers.

Technical & fundamental data as of Jun 26, 2026.

Open?$6.49
High?$7.40
Low?$6.47
Prev. Close?$6.66
Volume?15.6M
Avg. Volume?7.7M
VWAP?$7.06
Rel. Volume?2.02x
Bid / Ask
Bid?$6.25 × 100
Ask?$8.37 × 100
Spread?$2.12
Midpoint?$7.31
Valuation & Ratios
Market Cap?2.3B
Shares Out?305.4M
Float?208.7M
Float %?69.7%
P/E Ratio?N/A
P/B Ratio?2.40
EPS?-$0.47
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Employees
562
Market Cap
2.0B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2020-12-11
Address
150 W 4TH AVENUE
VANCOUVER, A1 V5Y 1G6
Phone: (604) 559-9005
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+2/3)
Medium-Term (Wave)? Bullish(+3/3)
Short-Term (Ripple)? Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
23
Z-Score?
87
Momentum?
50
Short Sent.?
45
Piotroski F-Score?3/9Weak
Altman Z-Score?3.66Safe
Confidence?61%Moderate
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?21.52%Squeeze Risk
Short Interest?44.9M
Days to Cover?7.1
Free Float208.7M
Avg Daily Volume6.3M
Settlement Date2026-06-15
Financial Health
Current Ratio?13.52Strong
Quick Ratio?13.52Strong
Cash Ratio?1.63Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A
P/B?
Peers
100
S&P
66
2.40CHEAP
P/S?
Peers
100
S&P
3
28.45HIGH
P/FCF?
N/A
EV/EBITDA?
S&P
97
-11.3CHEAP
EV/Sales?
Peers
100
S&P
3
27.48HIGH
Returns & Efficiency
ROE?
S&P
8
-15.4%WEAK
ROA?
S&P
3
-11.0%WEAK
Cash Flow & Enterprise
FCF?$-189231000
Enterprise Value?$2.2B
Fundamentals ratios updated end of day